Please reach us at brian@oncointegrate.com if you cannot find an answer to your question.
"My Health Profile" serves as a tool for OncoIntegrate to organize a user's health information, particularly related to cancer, into a draft protocol framework. It's designed for educational purposes and hypothesis generation, not as medical advice, diagnosis, or treatment. All outputs require review by an oncology team.
The profile requests detailed cancer-specific information including the primary diagnosis (cancer type, stage, hormone status), genetic mutations (from reports like FoundationOne®, Tempus, Caris), current conventional treatments (chemotherapy, endocrine therapy, immunotherapy, radiation), and specific cancer drug names (e.g., Keytruda, Carboplatin, Tamoxifen).
OncoIntegrate requests information on current prescription and over-the-counter medications, as well as active supplements, to flag potential conflicts for clinician review. This interaction screen is not a substitute for medical judgment. Additionally, information on other health conditions (like diabetes, hypertension), allergies, and organ function (liver and kidney status) helps the tool avoid suggesting inappropriate options and ensures a more comprehensive understanding of the user's health.
Information on previous treatments that were ineffective or not tolerated (e.g., "Tamoxifen—resistance after 2 years") is used to help the system avoid surfacing similar mechanisms in the draft ideas it generates. This aims to provide more relevant and potentially novel suggestions for exploration.
Yes, the profile offers a "Quick Fill from Document" feature that allows users to upload a medical document, test result, or screenshot. AI is then used to auto-extract details into the profile. However, users are strongly advised to review and edit everything before saving, as AI can make mistakes.
Users are advised to share only what they are comfortable adding and to avoid including sensitive identifiers that they wouldn't want exposed. While the tool is designed to help organize information, it emphasizes the user's discretion in providing personal details.
The inputs provided in "My Health Profile" allow OncoIntegrate to organize potential compound categories (such as metabolic, immune, microenvironment) and to structure specific protocol builders like Press-Pulse, Ferroptosis, and Mebendazole/Fenbendazole ± Ivermectin. This is solely for educational exploration. The system may also surface preclinical literature summaries relevant to the user's entries, but it does not recommend or endorse any therapy.
Yes, there is an "Additional Clinical Context (Optional)" area where users can include nuanced information that might shape the framework. This can include details such as diagnostic complexities, histology changes, key timeline notes, comorbidities, or prior adverse effects, allowing for a more personalized and comprehensive understanding.
The OncoIntegrate Protocol Builder is an educational tool designed to help users explore categories of compounds that have been studied in preclinical (lab and animal) research for potential anti-cancer properties. It organizes these compounds into draft protocol frameworks based on a user's health profile, including diagnosis, treatments, medications, supplements, genetics, and other health factors. It's important to note that this tool does not recommend or prescribe treatments; its outputs are hypothesis-generating only and must be reviewed with an oncology team.
Users can explore a wide range of categories, each representing a distinct mechanism or pathway studied in preclinical research. These include Anti-Angiogenic, Anti-Inflammatory, Anti-Metastatic / Neuroendocrine / Anti-Stress, Microbiome & Gut-Immune Axis, Mutation-Targeted, Tumor Microenvironment Modifiers, Pro-Apoptotic Compounds, Anti-Stem Cell Compounds, Metabolic Pathway Inhibitors (like Glucose, Glutamine, and Fatty Acid Pathway Inhibitors), Hormonal Pathway Modulators, Ferroptosis Inducers, Press-Pulse / Metabolic Cycling frameworks, Fenbendazole / Mebendazole ± Ivermectin, and Immune Supporting / Modulatory compounds. The tool also includes Conventional Therapies for reference.
The Protocol Builder utilizes information entered in a user's Health Profile, which includes details like diagnosis, current treatments, medications, supplements, genetics, and other health factors. This information allows OncoIntegrate to organize compounds into relevant draft protocol frameworks and help users identify potential areas of overlap or conflict.
No, the Protocol Builder explicitly states that it does not recommend or prescribe treatments. Its outputs are strictly hypothesis-generating and are intended for educational and organizational purposes only. All generated information and draft protocols must be reviewed and discussed with a qualified oncology team.
To use the Protocol Builder, users first select categories relevant to their cancer type, profile, or interests. Next, they review the compounds listed within each chosen category. Finally, they generate a draft protocol that organizes their selections, complete with references and interaction checks. This draft can then be exported as a professional-format PDF to be shared with their healthcare team.
As a user builds their protocol, the system can screen for potential overlaps or conflicts between their selected compounds and the medications/supplements listed in their health profile. This feature is AI-assisted, so errors can occur, and it is explicitly stated to be educational only, not a substitute for clinical review. Its purpose is to highlight potential issues for discussion with licensed healthcare professionals.
The categories cover a broad spectrum of mechanisms. For instance, Anti-Angiogenic compounds target tumor blood vessel formation, Pro-Apoptotic compounds aim to trigger programmed cell death, and Metabolic Pathway Inhibitors focus on starving tumors of key fuel sources like glucose, glutamine, or fatty acids. Other categories explore effects on inflammation, tumor spread, the gut microbiome, specific genetic mutations, and immune balance.
No, the information regarding antiparasitic drugs like Fenbendazole / Mebendazole ± Ivermectin is presented strictly for educational purposes. The tool notes that these drugs are discussed in preclinical research and patient communities, but OncoIntegrate provides an organizational framework for them, explicitly stating it is "strictly educational" and not a recommendation for treatment.
The OncoIntegrate Protocol Report is a personalized draft designed to help individuals organize information, reduce overwhelm, and prepare structured discussions with their oncology team. It brings together a complete patient profile, compound analysis, and dosing and scheduling frameworks for potential cancer-related interventions. It is explicitly stated to be for educational purposes only and not medical advice, requiring users to review and confirm all information with licensed healthcare professionals.
The "Complete Patient Profile" section of the report displays crucial patient-specific information. This includes the individual's cancer type, stage, hormone status, genetic mutations, current medications, supplements, allergies, and organ function. This comprehensive context is vital for ensuring that the compound frameworks generated in the report are tailored to the individual's unique background.
The "Compound Analysis" section provides detailed information for each selected compound. This includes a summary of preclinical research findings ("Evidence & Rationale"), the pathways studied in laboratory settings ("Mechanisms of Action" like metabolic inhibition or apoptosis), general dosing and administration ranges from research ("Dosing & Administration"), and commonly reported side effects, drug interactions, and contraindications ("Safety & Monitoring"). Examples provided include Curcumin and EGCG, highlighting their studied effects and potential limitations or side effects.
If a user enters genetic mutations in their Health Profile, the system performs a "Genetic Mutation Analysis." This feature highlights compounds that have preclinical evidence of activity against those specific genetic targets. For example, if a BRCA2 mutation is entered, the system might note that Curcumin has been studied for DNA damage modulation and tumor suppressor activation in relevant models. It's important to note that this section is hypothesis-generating only and should be interpreted with caution.
The "Protocol Scheduling & Planning" section organizes selected compounds into a proposed schedule, which can be daily, cycling, or advanced. Each schedule specifies a suggested dose (based on preclinical or early clinical references), timing (e.g., morning, evening), and a rationale explaining the intended educational purpose (e.g., "supporting metabolism with breakfast"). These schedules are customizable and are intended as a basis for discussion with the user's care team.
OncoIntegrate offers two "Advanced Protocol Generators": the Ferroptosis Protocol Builder and the Press–Pulse Protocol Builder. The Ferroptosis Protocol Builder explores compounds and strategies that may promote ferroptosis, an experimental form of iron-dependent cell death. The Press–Pulse Protocol Builder organizes continuous ("Press") and intermittent ("Pulse") strategies from metabolic oncology, aiming to simulate stress on cancer cells while maintaining safety. Both are strictly experimental, hypothesis-driven, and designed for educational exploration rather than prescription.
Ferroptosis is a form of iron-dependent cell death that is currently under investigation in cancer research. The OncoIntegrate report includes a "Ferroptosis Protocol Builder" which allows users to explore compounds and strategies that may promote this specific type of cell death. This builder focuses on oxidative stress and iron metabolism disruption as potential mechanisms. It is presented as a strictly experimental and hypothesis-driven tool, designed for exploration rather than prescription.
The OncoIntegrate Protocol Report comes with several crucial disclaimers and limitations. It is explicitly stated that all generated protocols are draft frameworks only, not prescriptions, and do not guarantee benefit. Users are required to acknowledge these disclaimers before generating or printing reports. The entire report is for educational purposes only and is not medical advice. Users are strongly reminded to always review and confirm all information with their licensed healthcare professionals before making any decisions. The intent is to provide an organized framework for discussion, not a definitive treatment plan.